FUSAROLI, MICHELE
FUSAROLI, MICHELE
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Dottorandi
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
2024 Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E.
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
2023 Pauline O.; Robert M.; Bernardeau C.; Hlavaty A.; Fusaroli M.; Roustit M.; Cracowski J.L.; Khouri C.
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct
2023 Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
2023 Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
2023 Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
2023 Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Ponti F.; Pelotti S.; Poluzzi E.
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study
2023 Fusaroli M.; Giunchi V.; Battini V.; Gringeri M.; Rimondini R.; Menchetti M.; Radice S.; Pozzi M.; Nobile M.; Clementi E.; De Ponti F.; Carnovale C.; Raschi E.; Poluzzi E.
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System
2023 Fusaroli M.; Simonsen A.; Borrie S.A.; Low D.M.; Parola A.; Raschi E.; Poluzzi E.; Fusaroli R.
Interpretation of Pharmacovigilance Disproportionality Analyses
2023 Khouri, Charles; Fusaroli, Michele; Salvo, Francesco; Raschi, Emanuel
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
2023 Fusaroli M.; Salvo F.; Bernardeau C.; Idris M.; Dolladille C.; Pariente A.; Poluzzi E.; Raschi E.; Khouri C.
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies
2023 Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Poluzzi E.
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
2022 Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G.
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
2022 Gaimari A.; Fusaroli M.; Raschi E.; Baldin E.; Vignatelli L.; Nonino F.; De Ponti F.; Mandrioli J.; Poluzzi E.
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
2022 Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F.
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System
2022 Noseda, Roberta; Müller, Laura; Bedussi, Francesca; Fusaroli, Michele; Raschi, Emanuel; Ceschi, Alessandro
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
2022 Fusaroli M.; Raschi E.; Giunchi V.; Menchetti M.; Rimondini Giorgini R.; De Ponti F.; Poluzzi E.
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal
2022 Raschi, Emanuel; Fusaroli, Michele; Gatti, Milo; Caraceni, Paolo; Poluzzi, Elisabetta; De Ponti, Fabrizio
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system
2022 Giunchi, V; Fusaroli, M; Lunghi, C; Zongo, A; Raschi, E; Poluzzi, E
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
2022 Fusaroli M.; Isgro V.; Cutroneo P.M.; Ferrajolo C.; Cirillo V.; Del Bufalo F.; Raschi E.; Poluzzi E.; Trifiro G.